跳至主要内容
临床试验/DRKS00009501
DRKS00009501已完成未知

Reducing the subjective experience of side effects during chemotherapy through education about the Nocebo-effect in therapy-naive patients with gastrointestinal tumors - RENNO study - RENNO Study

niversitätsklinikum Hamburg-Eppendorf0 个研究点目标入组 100 人开始时间: 2018年3月27日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. newly diagnosed tumor of gastrointestinal tract
  • 2. therapy-naive patient
  • 3. planned chemotherapy with/without monoclonal antibody (except EGFR-inhibitors) neoadjuvant, adjuvant or palliative
  • 4. ECOG < 2
  • 5. 18 years or older
  • 6. adequate knowledge of German language
  • 7. signed informed consent

排除标准

  • 1. prior chemotherapy
  • 2. combination of EGFR inhibitor (Cetuximab or Panitumumab) or combination with inhibitor of tyrosinkinase domain of EGF-receptor (Erlotonib)
  • 3. prior skin disease
  • 4. anamnestic chronic pulmonary disease
  • 5. dyspnea and skin disease before start of therapy
  • 6. acute mental stress or illness that may affect quality of life (physician's opinion)

研究者

发起方
niversitätsklinikum Hamburg-Eppendorf

相似试验